Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
Ivan Adamec, Dunja Rogić, Monika-Gabriele Penz, Carola Braun, Mario Habek
Topics & Concepts
OfatumumabCoronavirus disease 2019 (COVID-19)Multiple sclerosisVirologyMedicineCellular immunityImmunologyAntibodyImmune systemMonoclonal antibodyInternal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesLong-Term Effects of COVID-19